

**HP16-2024EPI  
QUESTIONS AND ANSWERS**

Please find below clarifying questions to be addressed related to the invitation to bid for HP16-2024EPI.

<b>Question</b>	<b>Answer</b>
1. We have noted inclusion of new vaccines and potential changes in schedule to accommodate the changes:	
a. What has led to proposed changes? (Including change in specifications)	Specifications are based on the disease prevalence within South Africa, and advice from the Ministerial Advisory Committee on EPI programme schedule and requirements
b. What is envisaged to be the programmatic impact?	The programme will continue to use a suitable vaccine, with possible health cost savings
c. If an alternative vaccine is awarded in HP 16-2024EPI versus HP16-2020EPI, when would NDoH cease to order, to mitigate supplier write off .	From the 1st of January 2024 the tender participating authorities e.g. provincial departments of health, will order the item awarded on HP 16-2024EPI tender. The new tender would be awarded approximately six months before the current tender HP16-2021EPI expires i.e.: 31 December 2023. This will give all relevant stakeholders enough time to transition into the new tender.
d. How would the NDoH manage transition to new registered vaccines with a higher valency within a tender period? .	Stock availability in the provinces will be considered, with a phased transition to the new tender item
2. Noting the budgetary constraints of the NDoH, what would be some of the additional considerations that the NDoH would consider as part of the bid adjudication?	Bids will be evaluated as per paragraph 2 of the SRCC. Recommendations or findings from the Departmental Bid adjudication Committee can not be pre-empted.
3. Training requirement of the bid that all contractors must collaborate with NDoH and provide end-users training on	Training needs may be identified based on various factors e.g. change in presentation, changing to a new vaccine on tender, changing of immunisation schedule, improving

Question	Answer
handling and vaccination process of their specific products as and when required within the duration of the contract – What does that entail? When would that be communicated?	demand for vaccines or supporting training of health care workers on the immunisation programme. This is ongoing process and training needs will be identified as they arise, and the supplier will be consulted during the process
4. Noting the transparency required with Tenders, has the NDoH considered non-disclosure of pricing?	As per the PFMA, non – disclosure of pricing is not allowed.
5. How will the negotiation of tender estimates and cost be managed?	Should any type of negotiations be considered / recommended, it could either be done via email correspondence or face to face meetings could be schedule

Relevance to SRCC	Question	Answer
Point 4.3 Samples  Point 20.1 Relevant to items 2, 12,13	For Item no 2 ( bOPV), Item no 12, 13 (MR) - to provide samples for products which are still in the registration process , application for permits need to be made to SAHPRA which normally takes around 6 to 8 weeks for approval – ultimately missing the timeline for samples for be submitted – can allowance can be provide for the items 2, 12,13	SRCC has been revised to allow for late submission of samples pending approved SAHPRA permit
Item List Pg 93 of Bid Pack	Item no 3 (Measles) and Item no 11 (Measles) are for the same vaccine specification with different volumes – Is it required to put in bids for each item.  Do we need to submit 2 X samples for each item number i.e. Item no 3 & 11?	No a single sample can be submitted but clearly indicate it is for item 3 and 11.  Yes

Relevance to SRCC	Question	Answer
	Do we need to submit MRC's, LICMI, LICM, PI for each Item even though they the same specification.	Yes
Item List Pg 93 of Bid Pack	Item no 4(TT) and Item no 15 (TT) are for the same vaccine specification with different volumes – Is it required to put in bids for each item.	No a single sample pack can be submitted, please specify the applicable item number it applies to.
	Do we need to submit 2 X samples for each item number?	Yes
	Do we need to submit MRC's, LICMI, LICM, PI for each Item even though they the same specification.	Yes
Item List Pg 93 of Bid Pack & Point 20.4.2 b) Introduction of Tdap	Item no 8 (Td)  The comment is made in 20.4.2b): the EPI schedule will change with the introduction of Tdap vaccine. This vaccine introduction will impact both the TT & Td – there is no number of doses on the introduction Table on PG 79 or 29 of SCC – what does this mean ? It is not similar to the other items where reduced estimates are then called for. Is there indication of when the proposed changes will be made to EPI schedule ?	With the introduction of the Tdap vaccine the TD vaccine will be phased out completely, while the TT volumes will be reduced to be used in emergency services only

Question	Answer
With respect to timing of product registrations in 2023. The Special conditions of contract, pt 20.2 makes reference to Items 2, 12 & 13 as it relates to registration after the closure of the bid at 19 September 2022.	

<p>a. Could you kindly consider making this provision for other vaccines pending registration in 2023, please?</p>	<p>No, this provision is only applicable to the bOPV and MR vaccines, based on the unavailability of registered products at the moment and the need to either continue use (bOPV) or introduce the MR vaccine based on the public health risk to South Africa</p>
<p>b. If our vaccine is pending registration between March (best case scenario) and August 2023 (worst case scenario), are we allowed to still submit a bid for this vaccine</p>	<p>No bids will be accepted after bid closure time and date.</p>
<p>2. Bid spec refers: Vaccine, rotavirus, containing the following as a minimum per vial, live attenuated human fully liquid in a pre-filled tube or plastic vial rotavirus strain not less than <math>10^6</math> CCID50 per dose. For oral administration</p>	
<p>a. Kindly confirm whether we may submit a bid if our product is <math>10^{56}</math> CCID50 per dose (rounded to the nearest number i.e. 6)</p>	<p>Please submit with specification deviation as recommended during the supplier engagement, for consideration</p>
<p>3. Clarity: Delivered price as per bid response Excel spreadsheet.</p> <p>Kindly confirm whether the delivered price is the price per vial or price per dose</p>	<p>The delivered price should be per vial (or as required by the specification in terms of pack size)</p> <p>In the event two or more equivalent vaccines are compared with different immunisation schedules e.g. a 2 dose schedule vs a 3 dose schedule, the cost per schedule will be considered, rather than the cost per dose. If vaccines with similar immunisation schedules but different vial presentation (single dose vs. multi-dose) are considered, the cost per dose will be used.</p>